Previous Close | 12.37 |
Open | 12.45 |
Bid | 0.00 x 1800 |
Ask | 0.00 x 2200 |
Day's Range | 11.90 - 12.57 |
52 Week Range | 8.86 - 33.97 |
Volume | |
Avg. Volume | 2,533,413 |
Market Cap | 1.702B |
Beta (5Y Monthly) | 1.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.26 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.81 |
Subscribe to Yahoo Finance Plus to view Fair Value for AUPH
Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Shares of the commercial-stage biopharma Aurinia Pharmaceuticals (NASDAQ: AUPH) rose by as much as 13.7% during Friday's trading session. This time around, Japanese drug manufacturer Otsuka Holdings is rumored to be considering a bid, according to a report posted on the subscription-based Betaville website and subsequently circulated on Twitter. Aurinia, for its part, has not commented on this takeover speculation.
VICTORIA, British Columbia, June 06, 2022--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)